Our breakthrough, proprietary technology platform engineered to enhance drug absorption
End-to-end, in-house control of formulation, development, and manufacturing capabilities
Our proprietary cannabinoid composition for the management of pain and inflammation
Partnering with the world’s leading research institutions and doctors to support FDA-authorized investigator-initiated clinical trials
Learn more about cannabidiol from the medical community and regulators
We are modernizing the way medicines are taken
Experts in drug development and delivery, manufacturing, and commercialization
Recent media coverage regarding Orcosa
Company news and announcements
November 13, 2020 – Today, Orcosa Inc. announced its official launch as a life sciences company seeking to modernize the way medicines are taken to improve patient outcomes through its proprietary therapeutic delivery technology, the Rapid Infusion Technology (RITe™) Platform.
Orcosa is the inventor, developer and exclusive owner of the RITe™ Platform – a fast acting, easy-to-take tablet engineered to enhance drug absorption. The tablet is designed to rapidly infuse an active pharmaceutical ingredient (API) through the tissue in the mouth and enable therapeutic effects quickly and efficiently. Based on the unique route of administration, the RITe™ Platform tablets have the ability to act faster and provide enhanced bioavailability over current formulations while reducing the potential for unwanted side effects for certain compounds.All RITe™ products will be manufactured at the company’s state-of-the-art cGMP-compliant facility in New Jersey.
Mark Ridall, Chief Executive Officer of Orcosa, said: “At its core, Orcosa has a singular focus – utilize our breakthrough, proprietary technology to modernize pharmaceutical delivery to improve patient treatments. There is a void between oral and intravenous delivery options, and we believe our RITe™ Platform not only helps fill this gap, but is fast, effective, safe and simple to use for all ages. With the support of our industry leading partners and respected investigators, our first product candidate, ORAVEXX™, is being studied to determine the reduction of pain and opioid use after shoulder arthroscopy. We are excited about the potential for ORAVEXX, but more importantly, the broad range of therapeutics and consumer products we intend to pursue in the years to come.”
Orcosa’s lead development program, ORAVEXX™, is a non-addictive proprietary cannabidiol (CBD) composition that utilizes the RITe™ Platform to treat pain and provide a safe, alternative treatment option to opioids. While early academic research supports cannabidiol as a pain treatment, poorly manufactured products with inaccurate dosing, low bioavailability, and difficult administration have made comprehensive empirical studies impractical and ineffective. ORAVEXX™ addresses these issues and provides researchers the opportunity to accurately determine the safety and efficacy of a CBD treatment through randomized controlled clinical trials.
The company has chosen to partner with leading research institutions and physicians to support FDA-authorized investigator-initiated clinical trials at world-class American research institutions to independently evaluate the safety and efficacy of ORAVEXX™ as an alternative pain management treatment to opioids.
Orcosa is led by an experienced management team, including:
About Orcosa Inc.
Orcosa Inc. is a life sciences company modernizing the way medicines are taken to improve patient outcomes through its proprietary therapeutic delivery technology, the Rapid Infusion Technology (RITe™) Platform. Orcosa is the inventor, developer and exclusive ownerof the RITe™ Platform, a fast acting, easy-to-take tablet engineered to enhance drug absorption. Orcosa’s lead development program, ORAVEXX™, is a non-addictive proprietary cannabidiol composition that utilizes the RITe™ Platform to treat pain and provide a safe, alternative treatment option to opioids. The company is currently supporting FDA-authorized investigator-initiated clinical trials at leading American research institutions to evaluate the safety and effectiveness of ORAVEXX™ as an alternative treatment to opioid therapy for pain management. For more information on Orcosa, please visit https://www.orcosa.com/.
Certain statements made herein constitute “forward-looking statements.” These forward-looking statements include, but are not limited to, the development of ORAVEXX™ and the RITe™ Platform. These statements are based on the current expectations of Orcosa and are not predictions of actual performance. Such forward-looking statements involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Orcosa to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.
Orcosa Inc.Sard Verbinnen & Co.Devin Broda214-687-8080